The 21-gene recurrence score assay demonstrated predictive value in terms of identifying whether patients with early-stage HR+, HER2- #breastcancer will require chemotherapy, in addition to endocrine therapy #bcsm
of discusses the importance of using genomic risk to tailor treatment to patients with early-stage HR+, HER2- disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy